Study for relapsed mantle cell lymphoma using targeted oral drugs
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests a combination of oral and antibody treatments for mantle cell lymphoma that has come back (relapsed) or did not respond (refractory). It aims to control the cancer and uses blood/tumor test results to guide some treatment timing for eligible participants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma confirmed by pathology review at the study site.
- Your lymphoma has either relapsed or is refractory after at least one treatment that included an anti-CD20 antibody, or you have not had prior anti-lymphoma treatment besides steroids or radiation (exact pathway depends on the study part).
- Your current illness needs treatment based on symptoms (swollen glands/spleen, pain from spread outside lymph nodes, organ problems from lymphoma, or “B symptoms” like fever/night sweats/major weight loss) or significant fatigue.
- You have measurable disease (a tumor or lymph node at least 1.5 cm) or you have bone marrow involvement causing low blood counts, or a significantly enlarged spleen.
- You can meet key blood and organ lab thresholds (including minimum white blood cells/neutrophils, platelets, hemoglobin, and kidney and liver tests) and you can provide required blood and bone marrow samples.
- If you are able to have pregnancy, you must use very effective birth control during treatment and for a specified time after the last dose (and breastfeeding/pregnancy are not allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
This Phase 2 study tests how well polatuzumab combined with bendamustine and rituximab works for mantle cell lymphoma that has come back or not responded. It may help shrink tumors and improve disease control, especially after prior treatment with ibrutinib.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This trial tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) for people with high-risk mantle cell lymphoma. The goal is to see if the combination works better than standard treatments, and it may be an option if your lymphoma has not responded well or has certain aggressive features.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.